Information Provided By: 
Fly News Breaks for May 2, 2019
AYX
May 2, 2019 | 08:29 EDT
KeyBanc analyst Brent Bracelin raised his price target for Alteryx to $100 form $85 after "strong" Q1 results, with revenue increasing 51% year over year to $76M. The analyst reiterates an Overweight rating on the shares.
News For AYX From the Last 2 Days
AYX
Apr 23, 2024 | 08:31 EDT
New option listings for April 23rd include Express Inc (EXPRQ). Option delistings effective April 23rd include PGT Innovations Inc (PGTI), NGM Biopharmaceuticals Inc (NGM), Karuna Therapeutics Inc (KRTX), KINNATE BIOPHARMA INC (KNTE), Daseke Inc (DSKE), Tritium Dcfc Ltd (DCFC), Xtrackers MSCI All China Equity ETF (CN), CymaBay Therapeutics Inc (CBAY), Alteryx Inc (AYX), XTRACKERS MSCI CHINA A INCLUSION EQUITY ETF (ASHX), Recro Pharma, Inc. (SCTL), Splunk Inc (SPLK), and Textainer Group Holdings Limited (TGH).
